Insulet Corporation $PODD Shares Sold by Jennison Associates LLC

Jennison Associates LLC reduced its stake in shares of Insulet Corporation (NASDAQ:PODD) by 55.2% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 108,354 shares of the medical instruments supplier’s stock after selling 133,363 shares during the period. Jennison Associates LLC owned 0.15% of Insulet worth $34,043,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of PODD. Inspire Investing LLC grew its position in shares of Insulet by 299.5% in the first quarter. Inspire Investing LLC now owns 4,119 shares of the medical instruments supplier’s stock valued at $1,082,000 after purchasing an additional 3,088 shares during the period. Gradient Investments LLC purchased a new stake in shares of Insulet in the second quarter valued at $17,429,000. Goldman Sachs Group Inc. grew its position in shares of Insulet by 1.9% in the first quarter. Goldman Sachs Group Inc. now owns 579,302 shares of the medical instruments supplier’s stock valued at $152,130,000 after purchasing an additional 10,628 shares during the period. Allspring Global Investments Holdings LLC grew its position in shares of Insulet by 55.5% in the first quarter. Allspring Global Investments Holdings LLC now owns 5,229 shares of the medical instruments supplier’s stock valued at $1,376,000 after purchasing an additional 1,867 shares during the period. Finally, Vident Advisory LLC purchased a new stake in shares of Insulet in the first quarter valued at $216,000.

Insulet Stock Down 1.3%

Shares of Insulet stock opened at $311.95 on Friday. The company has a fifty day moving average price of $326.94 and a 200 day moving average price of $306.52. The stock has a market cap of $21.96 billion, a price-to-earnings ratio of 94.82, a price-to-earnings-growth ratio of 2.64 and a beta of 1.40. Insulet Corporation has a twelve month low of $227.03 and a twelve month high of $353.50. The company has a current ratio of 2.26, a quick ratio of 1.81 and a debt-to-equity ratio of 0.64.

Insulet (NASDAQ:PODD) last issued its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $1.17 EPS for the quarter, topping analysts’ consensus estimates of $0.92 by $0.25. The company had revenue of $649.10 million for the quarter, compared to analysts’ expectations of $612.31 million. Insulet had a return on equity of 23.78% and a net margin of 10.01%.The firm’s quarterly revenue was up 32.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.55 earnings per share. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. Equities research analysts forecast that Insulet Corporation will post 3.92 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the company. Canaccord Genuity Group lifted their price objective on Insulet from $353.00 to $399.00 and gave the company a “buy” rating in a research report on Monday, September 29th. The Goldman Sachs Group dropped their price objective on Insulet from $399.00 to $375.00 and set a “buy” rating for the company in a report on Wednesday, October 1st. Rothschild & Co Redburn upped their price objective on Insulet from $350.00 to $370.00 and gave the stock a “buy” rating in a report on Friday, October 3rd. Leerink Partners upped their price objective on Insulet from $339.00 to $355.00 and gave the stock an “outperform” rating in a report on Tuesday, October 14th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Insulet in a report on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and two have given a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $352.11.

Insider Transactions at Insulet

In other Insulet news, SVP Prem Singh sold 687 shares of the business’s stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $347.49, for a total transaction of $238,725.63. Following the transaction, the senior vice president owned 3,456 shares in the company, valued at $1,200,925.44. The trade was a 16.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Laetitia Cousin sold 797 shares of the company’s stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $348.81, for a total transaction of $278,001.57. Following the completion of the transaction, the senior vice president directly owned 3,890 shares of the company’s stock, valued at approximately $1,356,870.90. The trade was a 17.00% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 0.39% of the company’s stock.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.